EP2049105A2 - Antimikrobielle photodynamische therapie - Google Patents

Antimikrobielle photodynamische therapie

Info

Publication number
EP2049105A2
EP2049105A2 EP07797049A EP07797049A EP2049105A2 EP 2049105 A2 EP2049105 A2 EP 2049105A2 EP 07797049 A EP07797049 A EP 07797049A EP 07797049 A EP07797049 A EP 07797049A EP 2049105 A2 EP2049105 A2 EP 2049105A2
Authority
EP
European Patent Office
Prior art keywords
gram
microorganisms
conjugate
spacer
photosensitizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07797049A
Other languages
English (en)
French (fr)
Other versions
EP2049105A4 (de
Inventor
Nikolay E. Nifantiev
Burkhard Gitter
Dmitri V. Yashunsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolitec AG
Original Assignee
Ceramoptec GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/880,974 external-priority patent/US20090030257A1/en
Application filed by Ceramoptec GmbH filed Critical Ceramoptec GmbH
Publication of EP2049105A2 publication Critical patent/EP2049105A2/de
Publication of EP2049105A4 publication Critical patent/EP2049105A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
EP07797049.9A 2006-07-27 2007-07-27 Antimikrobielle photodynamische therapie Withdrawn EP2049105A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83383606P 2006-07-27 2006-07-27
US11/880,974 US20090030257A1 (en) 2007-07-25 2007-07-25 Anti-microbial photodynamic therapy
PCT/US2007/016951 WO2009014524A2 (en) 2006-07-27 2007-07-27 Anti-microbial photodynamic therapy

Publications (2)

Publication Number Publication Date
EP2049105A2 true EP2049105A2 (de) 2009-04-22
EP2049105A4 EP2049105A4 (de) 2022-03-30

Family

ID=40282008

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07797049.9A Withdrawn EP2049105A4 (de) 2006-07-27 2007-07-27 Antimikrobielle photodynamische therapie

Country Status (4)

Country Link
EP (1) EP2049105A4 (de)
BR (1) BRPI0714667A8 (de)
MX (1) MX2009001074A (de)
WO (1) WO2009014524A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220061106A (ko) 2019-08-02 2022-05-12 코이트 헬스 오와이 전신적으로 적용하는 항생제의 항균 작용을 강화하는 방법
CN114053406B (zh) * 2021-11-23 2022-12-09 华中科技大学 一种多功能光热纳米杀菌材料及制备与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462070B1 (en) * 1997-03-06 2002-10-08 The General Hospital Corporation Photosensitizer conjugates for pathogen targeting
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
EP1610751A4 (de) * 2001-04-26 2006-05-24 Univ Texas Therapeutisches mittel/ligand-konjugat-zusammensetzungen, ihre syntheseverfahren und ihre anwendung
US20030176326A1 (en) * 2002-03-15 2003-09-18 Ceramoptec Industries Inc. Photosensitzers for photodynamic therapy of microbial infections
US20040186087A1 (en) * 2003-03-20 2004-09-23 Ceramoptec Industries, Inc. Siderophore conjugates of photoactive dyes for photodynamic therapy
AU2005204428A1 (en) * 2004-01-07 2005-07-28 Ambit Biosciences Corporation Conjugated small molecules
US8153111B2 (en) * 2004-06-18 2012-04-10 Ceramoptec Industries, Inc. Photo-triggered release of active substances from dendrimer-photosensitizer complexes

Also Published As

Publication number Publication date
WO2009014524A3 (en) 2020-10-15
BRPI0714667A2 (pt) 2013-08-06
BRPI0714667A8 (pt) 2016-10-18
WO2009014524A2 (en) 2009-01-29
EP2049105A4 (de) 2022-03-30
MX2009001074A (es) 2009-06-05

Similar Documents

Publication Publication Date Title
Nitzan et al. Eradication of Acinetobacter baumannii by photosensitized agents in vitro
Fu et al. Antimicrobial photodynamic therapy for methicillin‐resistant Staphylococcus aureus infection
US9308185B2 (en) Glyco-substituted dihydroxy-chlorins and β-functionalized chlorins for anti-microbial photodynamic therapy
Demidova et al. Photodynamic therapy targeted to pathogens
Jia et al. Cholesterol-assisted bacterial cell surface engineering for photodynamic inactivation of gram-positive and gram-negative bacteria
Hamblin et al. Rapid Control of Wound Infections by Targeted Photodynamic Therapy Monitored by In Vivo Bioluminescence Imaging¶
Dosselli et al. Synthesis, characterization, and photoinduced antibacterial activity of porphyrin-type photosensitizers conjugated to the antimicrobial peptide apidaecin 1b
Park et al. Antimicrobial effect of photodynamic therapy using a highly pure chlorin e6
Tang et al. A comparative in vitro photoinactivation study of clinical isolates of multidrug-resistant pathogens
US8404636B2 (en) Targeted delivery of antimicrobial agents
Chen et al. Aggregation‐induced emission‐based platforms for the treatment of bacteria, fungi, and viruses
Dosselli et al. Porphyrin− Apidaecin conjugate as a new broad spectrum antibacterial agent
Yang et al. Wheat germ agglutinin modified liposomes for the photodynamic inactivation of bacteria
US20040186087A1 (en) Siderophore conjugates of photoactive dyes for photodynamic therapy
US9216166B2 (en) Anti-microbial photodynamic therapy
Caruso et al. Enhanced photoinduced antibacterial activity of a BODIPY photosensitizer in the presence of polyamidoamines
Grimmeisen et al. Increasing the Selectivity of Light‐Active Antimicrobial Agents–Or How To Get a Photosensitizer to the Desired Target
Zheng et al. Poly (l-ornithine)-grafted zinc phthalocyanines as dual-functional antimicrobial agents with intrinsic membrane damage and photothermal ablation capacity
Turky et al. Antibacterial and in vitro anticancer activities of the antimicrobial peptide NRC‐07 encapsulated in chitosan nanoparticles
Scanone et al. Magnetic Nanoplatforms for In Situ Modification of Macromolecules: Synthesis, Characterization, and Photoinactivating Power of Cationic Nanoiman–Porphyrin Conjugates
Isaiah et al. Advances in efficacy enhancement of photosensitizer-mediated photodynamic antimicrobial chemotherapy
WO2013015774A1 (en) Glyco-substituted dihydroxy-chlorins and b-functionalized chlorins for anti-microbial photodynamic therapy
EP2049105A2 (de) Antimikrobielle photodynamische therapie
JP5049010B2 (ja) 光増感(photosensitisation)の使用
Kumar et al. Targeting bacterial biofilms using vancomycin and multivalent cell‐penetrating peptide labeled quantum dots

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOLITEC PHARMA IP & INVESTMENT LTD.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG

R17D Deferred search report published (corrected)

Effective date: 20201015

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210415

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031407000

Ipc: A61K0041000000

A4 Supplementary search report drawn up and despatched

Effective date: 20220225

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/04 20060101ALI20220221BHEP

Ipc: A61K 31/407 20060101ALI20220221BHEP

Ipc: A61K 47/64 20170101ALI20220221BHEP

Ipc: A61K 41/00 20060101AFI20220221BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240201